1
|
Vízkeleti L, Papp O, Doma V, Gil J, Markó-Varga G, Kovács SA, Győrffy B, Kárpáti S, Tímár J. Identification of genetic fingerprint of type I interferon therapy in visceral metastases of melanoma. Sci Rep 2024; 14:26540. [PMID: 39489756 PMCID: PMC11532416 DOI: 10.1038/s41598-024-77285-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2024] [Accepted: 10/21/2024] [Indexed: 11/05/2024] Open
Abstract
Malignant melanoma is a difficult-to-treat skin cancer with increasing incidence worldwide. Although type-I interferon (IFN) is no longer part of guidelines, several melanoma patients are treated with type-I interferon (IFN) at some point of the disease, potentially affecting its genetic progression. We run genome-wide copy number variation (CNV) analysis on previously type-I IFN-treated (n = 17) and control (n = 11) visceral metastases of melanoma patients. Results were completed with data from the TCGA and MM500 databases. We identified metastasis- and brain metastasis-specific gene signatures mostly affected by CN gains. Some cases were genetically resistant to IFN showing characteristic gene alterations (e.g. ABCA4 or ZEB2 gain and alterations of DNA repair genes). Analysis of a previously identified type-I IFN resistance gene set indicates that only a proportion of these genes was exclusive for the IFN-treated metastases reflecting a possible selective genomic pressure of endogenous IFNs during progression. Our data suggest that previous type-I IFN treatment and/or endogenous IFN production by immune response affect genomic progression of melanoma which may have clinical relevance, potentially influence immune checkpoint regulation in the tumor microenvironment.
Collapse
Affiliation(s)
- Laura Vízkeleti
- Department of Bioinformatics, Faculty of Medicine, Semmelweis University, 1094, Budapest, Hungary
- Department of Pathology, Forensic and Insurance Medicine, Faculty of Medicine, Semmelweis University, Üllői Str. 93., 1091, Budapest, Hungary
| | - Orsolya Papp
- Department of Pathology, Forensic and Insurance Medicine, Faculty of Medicine, Semmelweis University, Üllői Str. 93., 1091, Budapest, Hungary
- Turbine Simulated Cell Technologies, Budapest, 1027, Hungary
| | - Viktória Doma
- Department of Pathology, Forensic and Insurance Medicine, Faculty of Medicine, Semmelweis University, Üllői Str. 93., 1091, Budapest, Hungary
- Department of Dermatology, Venerology and Dermato-Oncology, Faculty of Medicine, Semmelweis University, 1085, Budapest, Hungary
| | - Jeovanis Gil
- Clinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical Engineering, Lund University, 223 63, Lund, Sweden
| | - György Markó-Varga
- Clinical Protein Science & Imaging, Biomedical Centre, Department of Biomedical Engineering, Lund University, 223 63, Lund, Sweden
- Chemical Genomics Global Research Lab, Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, 03722, South Korea
- 1St Department of Surgery, Tokyo Medical University, Tokyo, 160-8582, Japan
| | - Szonja A Kovács
- Department of Bioinformatics, Faculty of Medicine, Semmelweis University, 1094, Budapest, Hungary
- Doctoral School of Pathological Sciences, Semmelweis University, 1085, Budapest, Hungary
- National Laboratory for Drug Research and Development, 1117, Budapest, Hungary
| | - Balázs Győrffy
- Department of Bioinformatics, Faculty of Medicine, Semmelweis University, 1094, Budapest, Hungary
| | - Sarolta Kárpáti
- Department of Dermatology, Venerology and Dermato-Oncology, Faculty of Medicine, Semmelweis University, 1085, Budapest, Hungary
| | - József Tímár
- Department of Pathology, Forensic and Insurance Medicine, Faculty of Medicine, Semmelweis University, Üllői Str. 93., 1091, Budapest, Hungary.
| |
Collapse
|
2
|
Pinto de Almeida N, Jánosi ÁJ, Hong R, Rajeh A, Nogueira F, Szadai L, Szeitz B, Pla Parada I, Doma V, Woldmar N, Guedes J, Újfaludi Z, Bartha A, Kim Y, Welinder C, Baldetorp B, Kemény LV, Pahi Z, Wan G, Nguyen N, Pankotai T, Győrffy B, Pawłowski K, Horvatovich P, Szasz AM, Sanchez A, Kuras M, Rodriguez Murillo J, Betancourt L, Domont GB, Semenov YR, Yu K, Kwon HJ, Németh IB, Fenyő D, Wieslander E, Marko‐Varga G, Gil J. Mitochondrial dysfunction and immune suppression in BRAF V600E-mutated metastatic melanoma. Clin Transl Med 2024; 14:e1773. [PMID: 39032005 PMCID: PMC11259597 DOI: 10.1002/ctm2.1773] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2024] [Revised: 07/05/2024] [Accepted: 07/08/2024] [Indexed: 07/22/2024] Open
|
3
|
Szadai L, Guedes JDS, Woldmar N, de Almeida NP, Jánosi ÁJ, Rajeh A, Kovács F, Kriston A, Migh E, Wan G, Nguyen N, Oskolás H, Appelqvist R, Nogueira FCN, Domont GB, Yu K, Semenov ER, Malm J, Rezeli M, Wieslander E, Fenyö D, Kemény L, Horvath P, Németh IB, Marko‐Varga G, Gil J. Mitochondrial and immune response dysregulation in melanoma recurrence. Clin Transl Med 2023; 13:e1495. [PMID: 37990633 PMCID: PMC10663649 DOI: 10.1002/ctm2.1495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2023] [Revised: 11/09/2023] [Accepted: 11/15/2023] [Indexed: 11/23/2023] Open
Affiliation(s)
- Leticia Szadai
- Department of Dermatology and AllergologyUniversity of SzegedSzegedHungary
| | - Jéssica de Siqueira Guedes
- Clinical Protein Science & Imaging, Biomedical CentreDepartment of Biomedical EngineeringLund UniversityLundSweden
- Chemistry InstituteFederal University of Rio de JaneiroRio de JaneiroBrazil
| | - Nicole Woldmar
- Clinical Protein Science & Imaging, Biomedical CentreDepartment of Biomedical EngineeringLund UniversityLundSweden
- Chemistry InstituteFederal University of Rio de JaneiroRio de JaneiroBrazil
| | - Natália Pinto de Almeida
- Clinical Protein Science & Imaging, Biomedical CentreDepartment of Biomedical EngineeringLund UniversityLundSweden
- Chemistry InstituteFederal University of Rio de JaneiroRio de JaneiroBrazil
| | - Ágnes Judit Jánosi
- Department of Dermatology and AllergologyUniversity of SzegedSzegedHungary
| | - Ahmad Rajeh
- Department of DermatologyMassachusetts General HospitalHarvard Medical SchoolBostonMassachusettsUSA
| | - Ferenc Kovács
- Synthetic and Systems Biology UnitBiological Research CentreEötvös Loránd Research NetworkSzegedHungary
| | - András Kriston
- Synthetic and Systems Biology UnitBiological Research CentreEötvös Loránd Research NetworkSzegedHungary
| | - Ede Migh
- Synthetic and Systems Biology UnitBiological Research CentreEötvös Loránd Research NetworkSzegedHungary
| | - Guihong Wan
- Department of DermatologyMassachusetts General HospitalHarvard Medical SchoolBostonMassachusettsUSA
- Department of Biomedical InformaticsHarvard Medical SchoolBostonMassachusettsUSA
| | - Nga Nguyen
- Department of DermatologyMassachusetts General HospitalHarvard Medical SchoolBostonMassachusettsUSA
| | - Henriett Oskolás
- Section for Clinical ChemistryDepartment of Translational MedicineLund UniversityLundSweden
| | - Roger Appelqvist
- Clinical Protein Science & Imaging, Biomedical CentreDepartment of Biomedical EngineeringLund UniversityLundSweden
| | - Fábio CN Nogueira
- Chemistry InstituteFederal University of Rio de JaneiroRio de JaneiroBrazil
| | - Gilberto B Domont
- Chemistry InstituteFederal University of Rio de JaneiroRio de JaneiroBrazil
| | - Kun‐Hsing Yu
- Department of Biomedical InformaticsHarvard Medical SchoolBostonMassachusettsUSA
| | - Eugene R. Semenov
- Department of DermatologyMassachusetts General HospitalHarvard Medical SchoolBostonMassachusettsUSA
| | - Johan Malm
- Section for Clinical ChemistryDepartment of Translational MedicineLund UniversityLundSweden
| | - Melinda Rezeli
- Clinical Protein Science & Imaging, Biomedical CentreDepartment of Biomedical EngineeringLund UniversityLundSweden
| | - Elisabet Wieslander
- Section for Clinical ChemistryDepartment of Translational MedicineLund UniversityLundSweden
| | - David Fenyö
- Department of Biochemistry and Molecular PharmacologyInstitute for Systems GeneticsNew York University Grossman School of MedicineNew YorkUSA
| | - Lajos Kemény
- Department of Dermatology and AllergologyUniversity of SzegedSzegedHungary
| | - Peter Horvath
- Synthetic and Systems Biology UnitBiological Research CentreEötvös Loránd Research NetworkSzegedHungary
| | | | - György Marko‐Varga
- Clinical Protein Science & Imaging, Biomedical CentreDepartment of Biomedical EngineeringLund UniversityLundSweden
- Chemical Genomics Global Research LabDepartment of BiotechnologyCollege of Life Science and BiotechnologyYonsei UniversitySeoulSouth Korea
- First Department of SurgeryTokyo Medical UniversityTokyoJapan
| | - Jeovanis Gil
- Section for Clinical ChemistryDepartment of Translational MedicineLund UniversityLundSweden
| |
Collapse
|
4
|
Alsayyah A. Differentiating between early melanomas and melanocytic nevi: A state-of-the-art review. Pathol Res Pract 2023; 249:154734. [PMID: 37573619 DOI: 10.1016/j.prp.2023.154734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/06/2023] [Revised: 07/31/2023] [Accepted: 08/02/2023] [Indexed: 08/15/2023]
Abstract
Clinicians and dermatologists are challenged by accurate diagnosis of melanocytic lesions, due to melanoma's resemblance to benign skin conditions. Several methodologies have been proposed to diagnose melanoma, and to differentiate between a cancerous and a benign skin condition. First, the ABCD rule and Menzies method use skin lesion characteristics to interpret the condition. The 7-point checklist, 3-point checklist, and CASH algorithm are score-based methods. Each of these methods attributes a score point to the features found on the skin lesion. Furthermore, reflectance confocal microscopy (RCM), an integrated clinical and dermoscopic risk scoring system (iDscore), and a deep convoluted neural network (DCNN) also aids in diagnosis. RCM optically sections live tissues to reveal morphological and cellular structures. The skin lesion's clinical parameters determine iDscore's score point system. The DCNN model is based on a detailed learning algorithm. Therefore, we discuss the conventional and new methodologies for the identification of skin diseases. Moreover, our review attempts to provide clinicians with a comprehensible summary of the wide range of techniques that can help differentiate between early melanomas and melanocytic nevi.
Collapse
Affiliation(s)
- Ahmed Alsayyah
- Department of Pathology, College of Medicine, Imam Abdulrahman Bin Faisal University, Post Box No. 1982, Dammam 31441, Saudi Arabia.
| |
Collapse
|
5
|
Metastatic Progression of Human Melanoma. Cancers (Basel) 2023; 15:cancers15041225. [PMID: 36831566 PMCID: PMC9954442 DOI: 10.3390/cancers15041225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2023] [Revised: 02/08/2023] [Accepted: 02/13/2023] [Indexed: 02/17/2023] Open
Abstract
This Topical Collection, comprising 13 papers (10 original articles and 3 reviews), addresses various aspects of the field of melanoma progression: genomic and proteomic approaches, experimental studies, the questions of sentinel lymph node dissection, and metastasis formation of uveal and conjunctival melanomas is also discussed [...].
Collapse
|